Study to test efficacy, tolerability, safety and pharmacokinetics of Tofacitinib ointment in subjects with mild, moderate or severe chronic plaque psoriasis.

Registry ID

EUCTR2012-005645-20

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

Pfizer Inc. 235 East 42nd Street, New York, 10017

Start date

2013-06-25

Completion date

2014-09-16

Last update

2026-08-16

Conditions

• Chronic Plaque Psoriasis

Summary

1. To characterize the efficacy of tofacitinib ointment (10 mg/g and 20 mg/g) applied once daily (QD) or twice daily (BID) over 12 weeks in subjects with mild or moderate chronic plaque psoriasis compared to the corresponding placebo ointment (vehicle) (QD or BID). 2. To characterize safety of tofacitinib ointment (10 mg/g and 20 mg/g) applied QD or BID over 12 weeks in subjects with mild or moderate chronic plaque psoriasis. 3. To characterize local tolerability of tofacitinib ointment (10 mg/g and 20 mg/g) applied QD or BID over 12 weeks in subjects with mild or moderate chronic plaque psoriasis.

Locations

• , , Denmark

Related clinical trials

• To Check Comparison of Apremilast and Methotrexate Efficacy in Patients With Moderate to Severe Plaque Psoriasis Presented to Tertiary Care Hospital

View on source registry